ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
ThromboGenics NV (Leuven, Belgium) and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche (Basel, Switzerland) for their jointly developed anti-cancer agent TB-403.
ThromboGenics NV (Leuven, Belgium) and BioInvent International AB (Lund, Sweden) have entered into a license agreement with Roche (Basel, Switzerland) for their jointly developed anti-cancer agent TB-403. TB-403 is a novel monoclonal antibody, which blocks placental growth factor (PIGF), one of the growth factors responsible for the development of new blood vessels.
TB-403 is a humanized monoclonal antibody that blocks the formation of new blood vessels that are needed by solid tumors to support their growth. It has the potential to minimize both the growth and spread of cancer cells.
TB-403 (anti-PIGF) has completed an initial Phase 1 clinical trial and recently received approval to enter a Phase 1b dose escalation trial. This Phase 1b trial will be conducted in patients with advanced cancer and is due to commence shortly in Denmark.
Under the terms of the license agreement, Roche will pay ThromboGenics and BioInvent an upfront payment of €50 million. Roche will have a worldwide, exclusive license to develop and commercialize TB-403. ThromboGenics and BioInvent will retain co-promotion rights for the product in the Benelux, Baltic, and Nordic regions.
Roche will assume responsibility for all future development costs for this novel therapy, including the costs of the pending Phase 1b trial in patients to be run by ThromboGenics and BioInvent. Roche will also provide funding to ThromboGenics and BioInvent for research on non-cancer indications and supply of clinical material until transfer of manufacturing.
ThromboGenics release (PDF)
The Solution Lies with SOLBIOTE™: Achieving Sustainability, a Growing Focus in Biopharma
October 28th 2024The nexus between biopharmaceuticals and sustainability is seemingly far apart, however, it is increasingly recognized as an inevitable challenge. It is encouraged to take a sustainable approach to reducing the environmental impact of the production and supply of medicines while improving people's health; delivering the well-being of people and the planet. Yosuke Shimojo (Technical Value Support Section Manager, Nagase Viita) will unveil how SOLBIOTE™, a portfolio of injectable-grade saccharide excipients, would be a key for the biopharmaceutical development and achieving sustainability for a better future of the industry.
